Robotic Telesurgery Data from Collaboration with Corewell Health™ Accepted for Presentation at the Cardiovascular Research Technologies Annual Meeting
Microbot Medical Inc. (NASDAQ: MBOT) announced a significant milestone in its collaboration with Corewell Health™ on robotic telesurgery for endovascular applications. Research demonstrating the feasibility of using the LIBERTY® Endovascular Robotic System between separate facilities 5 miles apart in a coronary simulation model has been accepted for presentation at the Cardiovascular Research Technologies (CRT) annual meeting on March 10, 2025.
The study, led by Dr. Ryan Madder, Section Chief of Interventional Cardiology at Corewell Health™, will be presented by Dr. Trisha Gomez and published in the Journal of the American College of Cardiology (JACC) Interventions. Dr. Madder noted that the LIBERTY® system "functioned well in a telerobotic setting" with its small footprint and disposable design creating "exciting possibilities for future telerobotic endovascular procedures."
Microbot's CEO Harel Gadot emphasized that telesurgery capabilities are an important part of their long-term strategy, potentially increasing access to quality healthcare for patients in remote locations. The telesurgery feature is still under development and not covered under Microbot's pending 510(k) submission with the FDA.
Microbot Medical Inc. (NASDAQ: MBOT) ha annunciato un traguardo significativo nella sua collaborazione con Corewell Health™ per la telesurgery robotica in applicazioni endovascolari. La ricerca che dimostra la fattibilità dell'uso del LIBERTY® Endovascular Robotic System tra strutture separate di 8 km in un modello di simulazione coronarica è stata accettata per la presentazione al Cardiovascular Research Technologies (CRT) incontro annuale il 10 marzo 2025.
Lo studio, guidato dal Dr. Ryan Madder, Capo Sezione di Cardiologia Interventistica presso Corewell Health™, sarà presentato dalla Dr.ssa Trisha Gomez e pubblicato nel Journal of the American College of Cardiology (JACC) Interventions. Il Dr. Madder ha osservato che il sistema LIBERTY® "ha funzionato bene in un contesto telerobotico" con il suo ingombro ridotto e design monouso che crea "possibilità entusiasmanti per future procedure endovascolari telerobotiche."
Il CEO di Microbot, Harel Gadot, ha sottolineato che le capacità di telesurgery sono una parte importante della loro strategia a lungo termine, potenzialmente aumentando l'accesso a cure sanitarie di qualità per i pazienti in località remote. La funzionalità di telesurgery è ancora in fase di sviluppo e non è coperta dalla presentazione 510(k) in sospeso di Microbot presso la FDA.
Microbot Medical Inc. (NASDAQ: MBOT) anunció un hito significativo en su colaboración con Corewell Health™ en telesurgery robótica para aplicaciones endovasculares. La investigación que demuestra la viabilidad del uso del LIBERTY® Endovascular Robotic System entre instalaciones separadas por 8 km en un modelo de simulación coronaria ha sido aceptada para su presentación en la reunión anual de Cardiovascular Research Technologies (CRT) el 10 de marzo de 2025.
El estudio, liderado por el Dr. Ryan Madder, Jefe de Sección de Cardiología Intervencionista en Corewell Health™, será presentado por la Dra. Trisha Gomez y publicado en el Journal of the American College of Cardiology (JACC) Interventions. El Dr. Madder señaló que el sistema LIBERTY® "funcionó bien en un entorno telerobótico" con su pequeño tamaño y diseño desechable creando "posibilidades emocionantes para futuros procedimientos endovasculares telerobóticos."
El CEO de Microbot, Harel Gadot, enfatizó que las capacidades de telesurgery son una parte importante de su estrategia a largo plazo, potencialmente aumentando el acceso a atención médica de calidad para pacientes en ubicaciones remotas. La función de telesurgery aún está en desarrollo y no está cubierta bajo la presentación 510(k) pendiente de Microbot ante la FDA.
Microbot Medical Inc. (NASDAQ: MBOT)는 Corewell Health™와의 로봇 원격 수술 협력에서 중요한 이정표를 발표했습니다. 별도의 시설 간 8km 떨어진 지점에서 심장관 모형을 사용한 LIBERTY® Endovascular Robotic System의 사용 가능성을 보여주는 연구가 Cardiovascular Research Technologies (CRT) 연례 회의에서 2025년 3월 10일 발표될 예정입니다.
이 연구는 Corewell Health™의 중재 심장학 부서장인 Ryan Madder 박사가 이끌었으며, Trisha Gomez 박사가 발표하고 Journal of the American College of Cardiology (JACC) Interventions에 게재될 예정입니다. Madder 박사는 LIBERTY® 시스템이 "원격 로봇 환경에서 잘 작동했다"며 작은 공간과 일회용 디자인이 "미래의 원격 로봇 혈관 시술에 대한 흥미로운 가능성을 만들어낸다"고 언급했습니다.
Microbot의 CEO인 Harel Gadot는 원격 수술 기능이 장기 전략의 중요한 부분이며, 외딴 지역의 환자들에게 양질의 의료 서비스 접근성을 높일 수 있다고 강조했습니다. 원격 수술 기능은 아직 개발 중이며 Microbot의 FDA에 제출된 510(k) 신청서에는 포함되지 않습니다.
Microbot Medical Inc. (NASDAQ: MBOT) a annoncé une étape importante dans sa collaboration avec Corewell Health™ sur la télésurgery robotique pour des applications endovasculaires. Une recherche démontrant la faisabilité de l'utilisation du LIBERTY® Endovascular Robotic System entre des établissements séparés de 8 km dans un modèle de simulation coronarienne a été acceptée pour présentation lors de la réunion annuelle de Cardiovascular Research Technologies (CRT) le 10 mars 2025.
L'étude, dirigée par le Dr Ryan Madder, Chef de la section de cardiologie interventionnelle chez Corewell Health™, sera présentée par la Dr Trisha Gomez et publiée dans le Journal of the American College of Cardiology (JACC) Interventions. Le Dr Madder a noté que le système LIBERTY® "a bien fonctionné dans un environnement telerobotique" avec son faible encombrement et son design jetable créant "des possibilités passionnantes pour de futures procédures endovasculaires telerobotiques."
Le PDG de Microbot, Harel Gadot, a souligné que les capacités de télésurgery sont une partie importante de leur stratégie à long terme, ce qui pourrait augmenter l'accès à des soins de santé de qualité pour les patients dans des localités éloignées. La fonctionnalité de télésurgery est encore en cours de développement et n'est pas couverte par la soumission 510(k) en attente de Microbot auprès de la FDA.
Microbot Medical Inc. (NASDAQ: MBOT) hat einen bedeutenden Meilenstein in seiner Zusammenarbeit mit Corewell Health™ zur robotergestützten Telechirurgie für endovaskuläre Anwendungen bekannt gegeben. Eine Studie, die die Machbarkeit der Verwendung des LIBERTY® Endovascular Robotic System zwischen getrennten Einrichtungen, die 8 km voneinander entfernt sind, in einem koronaren Simulationsmodell demonstriert, wurde zur Präsentation auf der Cardiovascular Research Technologies (CRT) Jahrestagung am 10. März 2025 angenommen.
Die Studie, geleitet von Dr. Ryan Madder, Abteilungsleiter für interventionelle Kardiologie bei Corewell Health™, wird von Dr. Trisha Gomez präsentiert und im Journal of the American College of Cardiology (JACC) Interventions veröffentlicht. Dr. Madder bemerkte, dass das LIBERTY® System "in einem telerobotischen Setting gut funktionierte" und sein kleiner Platzbedarf sowie das Einwegdesign "aufregende Möglichkeiten für zukünftige telerobotische endovaskuläre Eingriffe" schaffen.
Der CEO von Microbot, Harel Gadot, betonte, dass die Telechirurgie-Funktionen ein wichtiger Bestandteil ihrer langfristigen Strategie sind, die möglicherweise den Zugang zu hochwertigen Gesundheitsdiensten für Patienten in abgelegenen Gebieten erhöhen. Die Telechirurgie-Funktion befindet sich noch in der Entwicklung und ist nicht in der ausstehenden 510(k)-Einreichung von Microbot bei der FDA enthalten.
- Successful demonstration of LIBERTY® system's feasibility in telerobotic setting
- Research accepted for presentation at prestigious CRT annual meeting
- Study to be published in Journal of the American College of Cardiology Interventions
- Strategic collaboration with established healthcare provider (Corewell Health)
- Potential to expand access to quality healthcare in remote locations
- Telesurgery feature still under development
- Not yet covered under pending 510(k) FDA submission
- Study to simulation model, not actual patients
Insights
Microbot Medical's announcement regarding its telesurgery research collaboration with Corewell Health™ represents a meaningful technical milestone that could eventually expand the company's addressable market for its LIBERTY® Endovascular Robotic System. The acceptance of this research for presentation at the prestigious Cardiovascular Research Technologies conference and publication in JACC Interventions provides important scientific validation of the concept's feasibility.
The successful demonstration of remote robotic coronary procedures between facilities 5 miles apart is technically significant, though investors should recognize this remains in a simulated coronary model rather than actual clinical use. Dr. Madder's positive assessment specifically highlights two key competitive advantages: the system's small footprint and disposable design – features that differentiate LIBERTY® from larger, more capital-intensive robotic systems currently dominating the market.
From a market perspective, telesurgery capabilities could substantially expand LIBERTY's value proposition by addressing the geographic maldistribution of specialized physicians. Rural and underserved communities often lack access to interventional cardiologists, creating a substantial market opportunity if regulatory and technical hurdles can be overcome. The disposable component business model could generate recurring revenue streams once the platform achieves market penetration.
However, several important caveats temper near-term investment implications:
- The core LIBERTY® system itself remains under FDA review with its 510(k) submission
- The telesurgery capability is explicitly noted as not included in the current regulatory submission
- Technical challenges including latency, connectivity reliability, and fail-safe mechanisms must be addressed for clinical implementation
- Reimbursement pathways for telesurgery procedures remain undefined
For Microbot Medical, with its
This development should be viewed as enhancing Microbot's long-term potential while having minimal impact on near-term financial performance, as significant revenue generation remains contingent on initial FDA clearance, commercial launch, and clinical adoption of the base LIBERTY® system.
Research Collaboration demonstrates the feasibility of using the LIBERTY® Endovascular Robotic System between separate and remote facilities in a coronary simulation model
BRAINTREE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today announced its collaboration with Corewell Health™ has reached another meaningful milestone. Under a collaboration agreement, Microbot Medical® and Corewell Health™ are working together to advance robotic telesurgery for endovascular applications. Led by Ryan Madder, M.D., Section Chief of Interventional Cardiology and Director of the Cardiac Cath Lab at Corewell Health™ in Grand Rapids, Michigan, the project assesses the feasibility of using LIBERTY® to perform simulated cardiovascular interventional procedures across two sites within the Corewell Health™ system located 5 miles apart. The research has been accepted for presentation at the Cardiovascular Research Technologies (CRT) annual meeting, being held from March 8-11, 2025, in Washington D.C., and will be published in the Journal of the American College of Cardiology (JACC) Interventions online edition.
- Abstract/Presentation Title: Feasibility of Telerobotic Coronary Artery Wiring Using A Novel Miniaturized Robotic System: A Pre-clinical Ex Vivo Study
- Presenter: Trisha Gomez, MD
- Presentation Date/Time: Monday, March 10, 2025, 4:12-4:20pm ET.
- Location: Theater #4
“In this study, the LIBERTY® robotic system functioned well in a telerobotic setting. The system’s small footprint and disposable design create a multitude of exciting possibilities for future telerobotic endovascular procedures,” commented Dr. Madder.
“We’re excited that this groundbreaking research, led by Dr. Madder and the Corewell Health team, has been selected for presentation, which we believe reflects the importance of integrating telesurgery in the future of healthcare,” commented Harel Gadot, Chairman, CEO and President. “Incorporating telesurgery capabilities is an important part of our long-term strategy for LIBERTY®, and we are pleased to demonstrate its feasibility. We believe that robotic telesurgery will increase access to high quality healthcare for patients in remote locations in the US and around the world.”
Cardiovascular Research Technologies (CRT) is a leading educational forum on new cardiovascular technology and procedures for physicians and health-care professionals. CRT provides a forum for exemplary education for interventional cardiologists, general cardiologists, cardiothoracic and vascular surgeons, catheterization laboratory managers, nurses and technologists, scientists and those with an interest in cardiovascular medicine.
The telesurgery feature of LIBERTY® is still under development at Microbot and is not covered under its pending 510(k) premarket submission with the U.S. Food and Drug Administration.
About Microbot Medical®
Microbot Medical Inc. (NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to improve the quality of care for millions of patients and providers globally. The Company has developed the world’s first single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems.
Further information about Microbot Medical® is available at http://www.microbotmedical.com.
Safe Harbor
Statements to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, the Company’s need for and ability to obtain additional working capital to continue its transition to a commercially focused company, market conditions, risks inherent in the development and/or commercialization of the LIBERTY® Endovascular Robotic System, including its potential telesurgery feature, uncertainty in the results of regulatory pathways and regulatory approvals, including whether the FDA will grant 510(k) clearance to commercially market the LIBERTY® Endovascular Robotic System in the United States, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Investor Contact: IR@microbotmedical.com
FAQ
What milestone did Microbot Medical (MBOT) achieve with Corewell Health in robotic telesurgery?
When and where will the MBOT telesurgery research be presented?
Who led the MBOT LIBERTY® robotic telesurgery research at Corewell Health?
What are the potential benefits of MBOT's LIBERTY® telesurgery capabilities?
Is the telesurgery feature of MBOT's LIBERTY® system FDA approved?
What advantages does the LIBERTY® system offer for telerobotic procedures according to researchers?
Where will the MBOT and Corewell Health telesurgery research be published?
